SynthesisBMC infectious diseases2026
Genetic diversity and drug resistance mutations of HIV-1 in Ghana: a systematic review of two decades.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the roll-out of antiretroviral therapy (ART), there has been a significant reduction in Human Immunodeficiency Virus 1 (HIV-1) related mortality and morbidity. Nonetheless, drug resistance has emerged significantly, affecting treatment outcomes, but there is limited surveillance of HIV-1 drug resistance and subtype diversity, which is critical for clinical decision-making on therapeutic choices as well as public health control measures. The goal of this systematic review was to analyze data from 2004 to 2024 on subtype diversity and drug resistance mutations (DRMs) among persons living with HIV-1 in Ghana.
methodsWe searched PubMed, Scopus, Cochrane CENTRAL, CINAHL Complete, Web of Science, and Google Scholar for cross-sectional and longitudinal studies reporting on HIV-1 subtype diversity, drug resistance, or both among individuals in Ghana published from 2004 to 2024 and reviewed according to PRISMA guidelines. The protocol for this review was registered with PROSPERO (CRD42024529606).
resultsA total of 2472 studies were screened, 28 were selected for full-text review, and 18 were included. The overall sample size was 2001 individuals. HIV-1 subtypes observed were CRF02_AG (68.9%), A (2.2%), A3 (1.7%), B (2.1%), C (0.6%), G (3.5%), CRF06_cpx (3.3%), CRF09_cpx (0.6%), and other recombinant forms (16.8%). Only one occurrence was observed each for Subtypes D and K. Key DRMs for NRTIs were documented, with M184V/I detected at 41.2%, followed by M41L (15.4%) and T215Y/F (11.8%). For NNRTIs, DRMs were in the set as K103N (28.4%), G190A/S (10.1%), and V106I/AT (10.7%). The DRMs for PI were primarily marked by M46I/L (25.0%), while I54V, L90M, and V82A were each identified in 12.5% of cases. The INSTIs accessory mutations observed were L74I/M (46.7%), E157Q (20.0%), G163R/K and T97A (13.3% each). Only two studies analyzed sequences for DRMs from the integrase gene; however, these were accessory DRMs and are not known to produce resistance to the current INSTI regimen. Also, mutational profiles varied notably by ART history, and key mutations in NRTIs, NNRTIs, and INSTIs were significantly associated with ART experience.
conclusionThe findings reveal CRF02_AG predominance and a considerable increase in NNRTI DRMs, highlighting the need for tailored therapies and continued surveillance to address emerging resistance in Ghana.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.